Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
lunes, septiembre 21
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Harvard Bioscience Inc
HBIO
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$8.00
0.05
0.63%
al cierre: Sep 21, 5:00 PM EST
$8.07
0.0728
0.91%
After hour: Sep 14, 5:49 PM EST
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
Harvard Bioscience Financials
Harvard Bioscience (HBIO) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Harvard Bioscience Sees FY2026 Sales $89.147M-$90.877M vs $88.600M Est.
Harvard Bioscience (NASDAQ:HBIO) sees FY2026 sales of $89.147 million-$90.877 million vs $88.600 million analyst estimate. Raises Full Year 2026 Revenue Guidance to 3%-5% Year Over Year Growth.
Benzinga Newsdesk
PRO
Harvard Bioscience Sees Q3 Sales $21.000M-$22.600M vs $21.850M Est
Harvard Bioscience (NASDAQ:HBIO) sees Q3 sales of $21.000 million-$22.600 million vs $21.850 million analyst estimate.
Benzinga Newsdesk
PRO
Harvard Bioscience Q2 Adj. EPS $(0.14) Beats $(0.21) Estimate, Sales $22.727M Beat $21.450M Estimate
Harvard Bioscience (NASDAQ:HBIO) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.21) by 33.33 percent. This is a 40 percent decrease over losses of $(0.10) per share from
Benzinga Newsdesk
PRO
Harvard Bioscience Sees Q2 Sales $20.500M-$22.500M vs $21.900M Est
Harvard Bioscience (NASDAQ:HBIO) sees Q2 sales of $20.500 million-$22.500 million vs $21.900 million analyst estimate.
Benzinga Newsdesk
PRO
Harvard Bioscience Q1 Adj. EPS $(0.33) Beats $(0.62) Estimate, Sales $20.755M Miss $21.200M Estimate
Harvard Bioscience (NASDAQ:HBIO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.62) by 46.77 percent. This is a 230 percent decrease over losses of $(0.10) per share from
Benzinga Newsdesk
Earnings Scheduled For May 12, 2026
Benzinga Insights
Privacy Manager